- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT03792750
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 2. fázis
- 1. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kína, 310016
- Local Institution
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Participants must have histologic or cytological confirmation of a solid tumor that is advanced with measureable disease per RECIST v1.1
- Participants must have received, and then progressed or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting
- Participants must have an ECOG performance status of less than or equal to 1
- Participants must have at least 1 lesion with measurable disease as defined by RECIST Version 1.1
Exclusion Criteria:
- Participants must not have suspected, known, or progressive CNS metastases, have untreated CNS metastases, or have the CNS as the only site of disease
- Participants with prior exposure to anti PD-1 or anti-PDL1 therapy
- Participants must not have a history of allergy to any of the study treatment components
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Experimental Arm A
2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy
|
Specified Dose on Specified Day
Specified Dose on Specified Day
Más nevek:
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
The Number of Participants Experiencing Adverse Events (AE)
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) to assess the safety and tolerability of BMS-986205. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Serious Adverse Events (SAE)
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing serious adverse events (SAEs) to assess the safety and tolerability of BMS-986205 Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experience Adverse Events (AE) Leading to Discontinuation
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants experiencing adverse events (AEs) leading to discontinuation to assess the safety and tolerability of BMS-986205 An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
Number of Participant Deaths
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants who died in each arm during the study to assess the safety and tolerability of BMS-986205.
|
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities in specific liver tests based on US conventional units to assess the safety and tolerability of BMS-986205. The number of participants with the following laboratory abnormalities will be summarized: ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN Total bilirubin > 1.5 x ULN and 2 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN with total bilirubin > 2 x ULN |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests
Időkeret: From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
The number of participants with clinical laboratory test abnormalities based on US conventional units to assess the safety and tolerability of BMS-986205. The number of subjects with the following laboratory abnormalities will be summarized: TSH > ULN WITH TSH <= ULN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) TSH < LLN WITH TSH >= LLN AT BASELINE WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN (Within a 2-week window after the abnormal TSH test date) WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN (Within a 2-week window after the abnormal TSH test date) WITH FT3/FT4 TEST MISSING (Within a 2-week window after the abnormal TSH test date) |
From first dose to 100 days after last dose of study therapy (up to approximately 2 years)
|
(Cmax) Maximum Observed Plasma Concentration
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The maximum observes plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(Tmax) Time of Maximum Observed Plasma Concentration
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The time of maximum observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(AUC(TAU)) Area Under the Concentration-time Curve in One Dosing Interval
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
The area under the concentration-time curve in one dosing interval was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 days 1, 14, Cycle 1 day 1
|
(CLT/F) Apparent Total Body Clearance
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
The apparent total body clearance was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14, Cycle 1 day 1
|
(T-HALF (Eff, AUC)) Effective Elimination Half-life
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The effective elimination half-life was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
T-HALF (eff, AUC) explains the degree of AUC accumulation observed.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(AI_CMAX) Accumulation Index
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of Cmax at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(AI_AUC ) Accumulation Index
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
The accumulation index was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
AI is calculated based on ratio of AUC(TAU) at steady state to after the first dose.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 14
|
(Ctrough) Trough Observed Plasma Concentration
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
The trough observed plasma concentration was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab.
|
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 day 2, 8, 14, Cycle 1 day 1, 2, Cycle 3, 5, 9, 13, and 17 day 1
|
(percentUR24) Percent Urinary Recovery Over 24 Hours
Időkeret: pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
The percent urinary recovery over 24 hours was collected to characterize the pharmacokinetics of BMS-986205 administered alone and in combination with nivolumab. BMS-986205 had minimal evaluable concentration in urine to derive the parameter. |
pre-dose, 1, 2, 3, 4, 6, 8 hours post dose on Cycle 0 Day 1 and 2
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Objective Response Rate (ORR)
Időkeret: From first dose up to approximately 2 years
|
ORR is defined as the total number of participants whose best overall response (BOR) is either a completer response (CR) or partial response (PR) divided by the total number of participants in the population of interest. Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator BOR is defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy. |
From first dose up to approximately 2 years
|
Best Overall Response (BOR)
Időkeret: From first dose up to approximately 2 years
|
BOR defined as the best response designation over the study as a whole, recorded between the dates of first dose until the last tumor assessment prior to subsequent therapy.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator
|
From first dose up to approximately 2 years
|
Duration of Response (DOR)
Időkeret: From first dose up to approximately 2 years
|
Duration of Response (DOR) is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first.
Assessed per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 by investigator.
|
From first dose up to approximately 2 years
|
Measurement of Serum Kynurenine Levels
Időkeret: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of kynurenine levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of Tryptophan Levels
Időkeret: Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Measurement of tryptophan levels were assessed to characterize the pharmacodynamic activity of BMS-986205 administered alone and in combination with nivolumab.
|
Baseline, pre-dose (C1D1), 6 hours post dose (C1D1), pre-dose (C1D2), and at disease progression (actually collected on C3D1, C6D1, C8D1, and end of treatment-an average of 12 cycles)
|
Number of Participants With Anti-drug Antibodies (ADA) to Nivolumab
Időkeret: Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
The number of participants with positive or negative anti-drug antibodies (ADA) to nivolumab was collected to characterize the immunogenicity of nivolumab when administered in combination with BMS-986205. Baseline ADA Positive: A subject with baseline ADA-positive sample. ADA Positive: A subject with at least one ADA-positive sample relative to baseline. Neutralizing Positive: At least one ADA-positive sample with neutralizing antibodies detected post-baseline ADA Negative: A subject with no ADA-positive sample after initiation of treatment. |
Baseline, pre-dose (C1D1, C3D1, every 4 Cycles from C5D1), end of treatment - an average of 12 cycles, and follow up. (up to approximately 2 years)
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- CA017-076
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Előrehaladott rák
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)ToborzásAnatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Korai stádiumú emlőkarcinóma | Anatómiai Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Egyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Fred Hutchinson Cancer CenterMég nincs toborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
University of Southern CaliforniaNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | Invazív emlőkarcinómaEgyesült Államok
-
National Cancer Institute (NCI)Aktív, nem toborzóRosszindulatú szilárd daganat | Anatómiai Stage III Breast Cancer AJCC v8 | Anatómiai Stage IV Breast Cancer AJCC v8 | Invazív emlőkarcinóma | Mell adenokarcinómaEgyesült Államok
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institute on Aging (NIA)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
Mayo ClinicNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8Egyesült Államok
-
City of Hope Medical CenterNational Cancer Institute (NCI)ToborzásAnatómiai stádiumú emlőrák AJCC v8 | Anatómiai Stage II Breast Cancer AJCC v8 | Anatómiai Stage III Breast Cancer AJCC v8 | HER2-negatív emlőkarcinómaEgyesült Államok
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BefejezveVékonybél adenokarcinóma | III. stádiumú vékonybél-adenokarcinóma AJCC v8 | IIIA stádiumú vékonybél adenokarcinóma AJCC v8 | IIIB stádiumú vékonybél adenokarcinóma AJCC v8 | IV. stádiumú vékonybél adenokarcinóma AJCC v8 | Vater adenokarcinóma ampulla | Stage III Ampull of Vater Cancer AJCC v8 | Stage... és egyéb feltételekEgyesült Államok
Klinikai vizsgálatok a BMS-986205
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)MegszűntNem reszekálható hepatocelluláris karcinóma | III. stádiumú hepatocelluláris karcinóma AJCC v8 | IIIA stádiumú hepatocelluláris karcinóma AJCC v8 | IV. stádiumú hepatocelluláris karcinóma AJCC v8 | IVA stádiumú hepatocelluláris karcinóma AJCC v8 | IVB stádiumú hepatocelluláris karcinóma AJCC v8 és egyéb feltételekEgyesült Államok
-
Thomas Jefferson UniversityBristol-Myers SquibbAktív, nem toborzóGége | Laphámsejtes karcinóma | Ajak | Szájüregi laphámsejtes karcinóma | GaratEgyesült Államok
-
Bristol-Myers SquibbBefejezveMelanóma | Bőr rákEgyesült Államok, Kanada, Hollandia, Spanyolország, Ausztrália, Olaszország, Japán, Németország, Írország, Egyesült Királyság, Csehország, Svájc, Lengyelország, Franciaország, Görögország, Új Zéland
-
PDL BioPharma, Inc.MegszűntColitis ulcerosaBelgium, Franciaország, Egyesült Államok, Olaszország, Ausztrália, Cseh Köztársaság, Hollandia, Írország, Norvégia, Kanada, Ausztria, Németország, Magyarország, Ukrajna
-
Northwestern UniversityNational Cancer Institute (NCI)Aktív, nem toborzó
-
Bristol-Myers SquibbBefejezveEgészséges önkéntesekEgyesült Államok
-
Bristol-Myers SquibbBefejezve
-
Bristol-Myers SquibbBefejezveElőrehaladott rákEgyesült Államok, Izrael, Ausztrália, Ausztria, Kanada, Olaszország
-
National Alliance on Mental Illness New HampshireJanssen Medical AffairsMegszűntPszichotikus zavarokEgyesült Államok
-
Bristol-Myers SquibbBefejezveEgészséges résztvevőkEgyesült Királyság